imatinib mesylate has been researched along with Adenoma Sebaceum in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chada, K; D'Armiento, JM; Shiomi, T; Sonett, J; Unachukwu, U; Woode, D | 1 |
| Koluman, B; Yağci, M; Yegin, ZA | 1 |
| Amin, MB; Arbiser, JL; Bai, X; Claesson-Welsh, L; Govindarajan, B; Kazlauskas, A; Lim, SD; Onda, H | 1 |
3 other study(ies) available for imatinib mesylate and Adenoma Sebaceum
| Article | Year |
|---|---|
Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis.
Topics: Angiomyolipoma; Animals; Apoptosis; Imatinib Mesylate; Kidney Neoplasms; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; TOR Serine-Threonine Kinases; Tuberous Sclerosis; Tumor Suppressor Proteins; Tyrosine Kinase Inhibitors | 2023 |
The role of tyrosine kinase inhibitors in tuberous sclerosis.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure; Tuberous Sclerosis | 2009 |
Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis.
Topics: Benzamides; Biological Assay; Cell Line; Enzyme Inhibitors; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Tuberous Sclerosis | 2002 |